SCHEMBL279746

SCHEMBL279746

Cc1cc(C(=O)CSc2ccncc2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.44
KMT2A Q03164 3/20 0.43
NPC1 O15118 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 4/20 0.43
ALDH1A1 P00352 3/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
IMPDH2 P12268 1/20 0.41
IMPDH1 P20839 1/20 0.41
HPGD P15428 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13182758 0.77 KMT2A (0.60) KMT2ANPC1MEN1LMNAALDH1A1
SCHEMBL13060968 0.74 RAB9A (0.50) DAOKMT2ANPC1MEN1LMNA
SCHEMBL9787096 0.73 ALDH1A1 (0.59) KMT2ANPC1MEN1LMNAALDH1A1
SCHEMBL279925 0.73 KMT2A (0.45) DAOKMT2ANPC1MEN1LMNA
SCHEMBL9702849 0.71 ALDH1A1 (0.57) KMT2ANPC1MEN1LMNAALDH1A1
SCHEMBL13006685 0.71 ALDH1A1 (0.60) KMT2ANPC1MEN1LMNAALDH1A1
SCHEMBL13113137 0.69 PKM (0.51) KMT2AMEN1LMNAALDH1A1PKM
SCHEMBL10511018 0.69 DAO (0.61) DAOKMT2ANPC1LMNAALDH1A1
SCHEMBL12124435 0.69 LMNA (0.70) KMT2ANPC1MEN1LMNAALDH1A1
SCHEMBL147071 0.67 FFAR1 (0.65) KMT2AMEN1LMNAALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL DAO 1673/4885KMT2A 3398/4885NPC1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.